Analytical Data
-
基因名
HDAC6
- Application
-
别名
HD6; JM21
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UBN7
-
表达区间
Ser479~Arg835
-
分子量
70kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that plays a crucial role in regulating various cellular processes, including protein degradation, cytoskeletal dynamics, and stress responses. Unlike classical HDACs that primarily target histones, HDAC6 uniquely deacetylates non-histone proteins, such as tubulin and heat shock protein 90 (HSP90), thereby influencing cell motility and apoptosis. Overexpression of HDAC6 has been linked to several pathological conditions, particularly cancer and neurodegenerative diseases, where its activity can promote tumor progression and neurotoxic responses. Given its significant involvement in these diseases, HDAC6 has emerged as a promising therapeutic target. Researchers are increasingly focused on the development of HDAC6 inhibitors, which may offer novel treatment strategies for conditions characterized by dysregulated acetylation. Exploring the structural and functional properties of recombinant HDAC6 proteins allows for a better understanding of its enzymatic mechanisms and interactions with substrates, which is essential for rational drug design. Additionally, the study of HDAC6's role in cellular signaling pathways has potential implications in the fields of regenerative medicine and immunology. As such, the comprehensive understanding of HDAC6 function and modulation can pave the way for innovative therapeutic interventions aimed at mitigating the impact of its dysregulation in various diseases.












